Built for biotech investors
A new 8-K isn't useful by itself. A trial readout isn't useful by itself. What matters is whether the new evidence strengthens or weakens the reason you own the stock.
RP1's third FDA submission tests whether a prioritized resubmission can overcome two prior CRLs in anti-PD-1-failed melanoma.
RP1 plus nivolumab targets advanced melanoma that has progressed on anti-PD-1 therapy. The thesis turns on whether FDA approves the BLA resubmission before the Q1 2027 cash runway runs out.
Key Catalyst
FDA decision on RP1 BLA resubmission
Bull: Approval validates IGNYTE's 34% ORR and 24.8-month median DOR, unlocks a $120M financing tranche, and extends runway past Q1 2027.
Bear: A third CRL — the likeliest failure mode — forces a distressed financing as runway expires in Q1 2027.
A continuously growing research base
200+
companies covered
3,000+
SEC filings analyzed
14,000+
structured data points
1,300+
milestones tracked
The biggest losses rarely come from a bad thesis.
They come from failing to recognize when the thesis changed. Every filing, earnings call, and trial readout required you to re-evaluate. Most investors don't. The conviction drifts. The thesis goes stale.
You're left holding a position you haven't actually re-evaluated in months.
Radar catches the change — across everything you own.
Positive developments · 3
Thesis risks · 2
Why not just use AI?
AI
readouts.ai
Thesis status
The core argument is unchanged. Recent evidence confirms or is neutral to the thesis. No material shift has occurred.
A specific event has created meaningful uncertainty. The thesis could still hold — but it needs a positive resolution to remain valid.
The primary reason to own the stock has been removed. A CRL, trial failure, or structural change that eliminates the core value driver.
How it works
Bull case, bear case, conviction level, key risk. Generated from SEC filings and public disclosures. Already there when you arrive.
New 8-K drops, a trial reads out, an earnings call happens. Within minutes, the thesis is reconciled against the new information automatically.
Interrogate the bull case, stress-test the bear case, ask any question. The heavy lifting is done. You bring the judgment.
Ask anything
Interrogate the pipeline, stress-test the bear case, challenge the conviction — in plain language, instantly.
FDA rejected RP1 twice already. Why would a third submission succeed?
The prior CRLs cited contribution-of-effect deficiency — FDA wanted randomized evidence that RP1 added benefit over nivolumab alone. The resubmission doesn't address that with new data; it argues the 34% ORR and 24.8-month median DOR in anti-PD-1-failed patients are clinically meaningful on their own. That's a regulatory judgment call. The thesis holds only if FDA accepts single-arm data in this population — which it has done before (lifileucel), but not consistently.
Live coverage
Every covered company,
one living thesis.
Real theses, updated this week. Click any company to see the full thesis, catalyst timeline, and ask questions.
The problem isn't “I don't know how to read an 8-K.” The problem is “I own 20 biotech stocks and don't have time to continuously reassess each thesis.” readouts.ai pays for itself the first time it catches a thesis change you would have missed.
7-day free trial — $20/month forever, locked in as an early adopter
Every covered company, one thesis — updated as the story changes. Follow what you own, ask what you need to know.